Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for WAVE Life Sciences's OCF Margin % or its related term are showing as below:
WVE'
s OCF Margin % Range Over the Past 10 Years
Min: -3501.81 Med: -508.26 Max: -17.15
Current: -256.28
During the past 13 years, the highest OCF Margin % of WAVE Life Sciences was -17.15%. The lowest was -3501.81%. And the median was -508.26%.
WVE's OCF Margin % is ranked worse than 64.11% of 950
companies
in the Biotechnology industry
Industry Median: -64.565
vs WVE: -256.28
WAVE Life Sciences OCF Margin % Related Terms
WAVE Life Sciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WAVE Life Sciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (WVE) has a OCF Margin % of -155.71% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on WAVE Life Sciences and its competitors. According to the industry distribution chart, WAVE Life Sciences ranks #609 out of 950 companies in the Biotechnology industry, placing it in the top 64.1%.
Is WAVE Life Sciences' OCF Margin % too high?
WAVE Life Sciences' current OCF Margin % is -155.71%. Based on the distribution chart, WAVE Life Sciences ranks #609 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' OCF Margin % compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #609 out of 950 companies for OCF Margin %. This places WAVE Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on WAVE Life Sciences and its competitors. WAVE Life Sciences's current OCF Margin % is -155.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $6.03 — trading 38.3% above its estimated fair value. The current OCF Margin % is -155.71%. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For WAVE Life Sciences (WVE), the current OCF Margin % is -155.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of $6.03 is trading 38.3% above its estimated GF Value™ of $4.36.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for WVE:
OCF Margin %: -155.71%
GF Value™: $4.36 vs. price of $6.03 (38.3% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for WVE
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
